Thomas S H, Higham P D, Hartigan-Go K, Kamali F, Wood P, Campbell R W, Ford G A
Wolfson Dept of Clinical Pharamacology, University of Newcastle.
Br Heart J. 1995 Jul;74(1):53-6. doi: 10.1136/hrt.74.1.53.
Terodiline, an antimuscarinic and calcium antagonist drug, was used to treat detrusor instability but was withdrawn in 1991 after provoking serious ventricular arrhythmias associated with increases in the corrected QT interval (QTc). This research was performed to relate drug induced electrocardiographic changes in asymptomatic recipients to plasma concentrations of the R(+) and S(-) terodiline enantiomers.
Urological and geriatric clinics and wards.
Asymptomatic patients taking terodiline in stable dose.
Electrocardiograms (50 mm/s) were collected from patients while they were taking terodiline and compared with ECGs obtained before or after terodiline. QT interval, heart rate corrected QT interval (QTc), and QT dispersion (QTd) were measured. Drug induced electrocardiographic changes were related to plasma concentrations of R(+) and S(-) terodiline.
During terodiline treatment mean QTc and QTd were prolonged (491(43) and 84 (35) ms 1/2) compared with measurements made off therapy (443 (33) and 42 (17) ms 1/2, paired t tests, P < 0.002 and P < 0.01 respectively) in the 12 patients in sinus rhythm. The mean (95% confidence interval) drug induced increases were 48 (23 to 74) ms 1/2 for QTc and 42 (13 to 70) ms 1/2 for QTd. These increases correlated with total plasma terodiline (QTc: r = 0.77, P < 0.006, QTd: r = 0.68, P < 0.025) and with plasma concentrations of both terodiline enantiomers.
Terodiline increases QTc and QTd in a concentration dependent manner. It is not clear whether this is a stereoselective effect and, if so, which enantiomer is responsible. The results suggest that drug induced torsade de pointes is a type A (concentration dependent) adverse drug reaction.
特罗地林是一种抗毒蕈碱和钙拮抗剂药物,曾用于治疗逼尿肌不稳定,但在1991年因引发严重室性心律失常并伴有校正QT间期(QTc)延长而被撤市。本研究旨在探讨无症状受试者中药物诱导的心电图变化与R(+)和S(-)特罗地林对映体血浆浓度之间的关系。
泌尿外科和老年病科门诊及病房。
服用稳定剂量特罗地林的无症状患者。
在患者服用特罗地林期间收集心电图(50 mm/s),并与服用特罗地林之前或之后获得的心电图进行比较。测量QT间期、心率校正QT间期(QTc)和QT离散度(QTd)。将药物诱导的心电图变化与R(+)和S(-)特罗地林的血浆浓度相关联。
在12例窦性心律患者中,与未治疗时的测量值相比(分别为443(33)和42(17)ms 1/2,配对t检验,P<0.002和P<0.01),特罗地林治疗期间平均QTc和QTd延长(分别为491(43)和84(35)ms 1/2)。药物诱导的平均(95%置信区间)增加为QTc 48(23至74)ms 1/2,QTd 42(13至70)ms 1/2。这些增加与总血浆特罗地林相关(QTc:r = 0.77,P<0.006,QTd:r = 0.68,P<0.025),也与两种特罗地林对映体的血浆浓度相关。
特罗地林以浓度依赖性方式增加QTc和QTd。目前尚不清楚这是否是一种立体选择性效应,如果是,哪种对映体起作用。结果表明,药物诱导的尖端扭转型室速是一种A型(浓度依赖性)药物不良反应。